A strategy for more inclusive diagnosis pathways & representative clinical trials

AstraZeneca

Uncovering the barriers to disease diagnosis and clinical trial participation and developing a vision & strategy to address them.

The Challenge

Supporting AstraZeneca in improving the diversity of their clinical trials.

Marginalised racial and ethnic groups, as well as women have been historically underrepresented in clinical trials. This has lead to a lack of data of huge numbers of our global population. AstraZeneca wanted to tackle this by improving clinical trial recruitment.

The Solution

Utilizing our research and understanding of the user to develop an action plan to overcome barriers to disease diagnosis and clinical trial participation across AstraZeneca’s many clinical trials.

The Execution

Immersion in the current diagnosis & trials process & interviews with KOLs to uncover who is underserved & why.

Exploration of how adjacent trials and organizations encourage participation and drive diversity & inclusion to inform & inspire.

A comprehensive understanding of the barriers to diagnosis & clinical trial participation that exist today.

Stakeholder workshopping to align on a north star. Development of an action plan to overcome barriers to disease diagnosis & clinical trial participation.

The Impact

Creating a vision & strategy to bring about a fairer future

Creating the opportunity to build trust with patients, promote fairness and generate valuable biomedical data to support future drug development.

Speak to our experts about your unique challenge

Whether you’re identifying your next innovation priority, or looking to accelerate development of an existing concept, our team will have advice to help you move forward.

Tell us about your challenge